VAM
EIGR

Visium Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Visium Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23
Closed -$13K – 1231
2015
Q2 		$13K Sell
23
-5
-18% -$13.8K ﹤0.01% 1100
2015
Q1 		$242K Buy
+28
New +$245K ﹤0.01% 873
2014
Q4 		– Sell
-709
Closed -$3.34M – 1228
2014
Q3 		$3.34M Sell
709
-28
-4% -$148K 0.05% 374
2014
Q2 		$5.31M Sell
737
-79
-10% -$395K 0.08% 222
2014
Q1 		$4.38M Buy
+816
New +$3.86M 0.07% 256

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Visium Asset Management's EIGR Position: Q3 2015 in Review

Visium Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2015, closing a stake of 23 shares — an estimated $13K sold.

Visium Asset Management first reported a position in EIGR in Q1 2014 and held it in 5 quarters. The position peaked at $5.31M in Q2 2014. 41 funds tracked by Wall St. Rank hold EIGR as of Q3 2015.

  • Visium Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 23 Eiger BioPharmaceuticals, Inc. shares in Q3 2015, an estimated $13K.
  • Visium Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
  • Visium Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $5.31M in Q2 2014.
  • 41 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.